These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 29557414)

  • 1. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial.
    Kobyliak N; Abenavoli L; Mykhalchyshyn G; Kononenko L; Boccuto L; Kyriienko D; Dynnyk O
    J Gastrointestin Liver Dis; 2018 Mar; 27(1):41-49. PubMed ID: 29557414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study.
    Kobyliak N; Abenavoli L; Falalyeyeva T; Mykhalchyshyn G; Boccuto L; Kononenko L; Kyriienko D; Komisarenko I; Dynnyk O
    Minerva Med; 2018 Dec; 109(6):418-428. PubMed ID: 30221912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial.
    Kobyliak N; Falalyeyeva T; Mykhalchyshyn G; Kyriienko D; Komissarenko I
    Diabetes Metab Syndr; 2018 Sep; 12(5):617-624. PubMed ID: 29661605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; Elzehery R; Elhelaly R; Zalata K; Abdelsalam M; Eldeeb AA; Awad M; Elgamal A; Attia A; El-Wakeel N; Eldars W
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1237-1246. PubMed ID: 30096092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.
    Khan MY; Mihali AB; Rawala MS; Aslam A; Siddiqui WJ
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):703-715. PubMed ID: 31009401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 7. Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers.
    Al-Muzafar HM; Amin KA
    BMC Complement Altern Med; 2017 Jan; 17(1):43. PubMed ID: 28086768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.
    Aller R; De Luis DA; Izaola O; Conde R; Gonzalez Sagrado M; Primo D; De La Fuente B; Gonzalez J
    Eur Rev Med Pharmacol Sci; 2011 Sep; 15(9):1090-5. PubMed ID: 22013734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Farsi F; Mohammadshahi M; Alavinejad P; Rezazadeh A; Zarei M; Engali KA
    J Am Coll Nutr; 2016; 35(4):346-53. PubMed ID: 26156412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial.
    Behrouz V; Aryaeian N; Zahedi MJ; Jazayeri S
    J Food Sci; 2020 Oct; 85(10):3611-3617. PubMed ID: 32885440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease.
    El Amrousy D; El-Afify D
    Cytokine; 2020 Nov; 135():155215. PubMed ID: 32731119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease.
    Sheng X; Che H; Ji Q; Yang F; Lv J; Wang Y; Xian H; Wang L
    Horm Metab Res; 2018 May; 50(5):397-402. PubMed ID: 29723898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Loman BR; Hernández-Saavedra D; An R; Rector RS
    Nutr Rev; 2018 Nov; 76(11):822-839. PubMed ID: 30113661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW.
    Chaves FGB; Oliveira GF; Ribeiro JP; Serafim JV; Cordeiro LFM; Alvares MA; Cecchi MT; Vasquez MC; Souza TBD; Rullo VEV
    Rev Paul Pediatr; 2021; 39():e2019226. PubMed ID: 32876312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.